Celularity Inc.

About

Celularity is a clinical and commercial stage biotechnology company focused on cellular and regenerative medicine, specializing in off-the-shelf placental-derived allogeneic cell therapies and biomaterial products aimed at addressing serious unmet medical needs. The company believes in leveraging the unique biology of the placenta to create effective, accessible, and affordable therapeutics.

Verified company data

Cash position

$38.0 million

Shares outstanding

217828609

Projects

["CYNK-001 is a cryopreserved, allogeneic, off-the-shelf, natural killer (NK) cell therapy candidate derived from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers, solid tumors, and infectious disease. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity.\n\nIn preclinical studies, CYNK-001 demonstrated a range of biological activities expected of NK cells, including expression of perforin and granzyme B, cytolytic activity against hematological tumors and solid tumor cell lines, and secretion of immunomodulatory cytokines such as IFN-γ in the presence of tumor cells. CYNK-001 cells express NKG2D and CD94, as well as NK activating receptors DNAM1, NKp30, NKp46, and NKp44.","CYNK-101 is a cryopreserved, off-the-shelf, allogeneic NK cell product candidate, overexpressing a high IgG binding affinity, proteinase cleavage resistant, CD16 variant. The results show the synergistic effect of combining CYNK-101 with daratumumab to drive antibody dependent cellular cytotoxicity activity against CD38+ hematological malignancies in vitro and in vivo. In these studies, CYNK-101 was not susceptible to daratumumab-directed fratricide and did not display on-target, off-tumor cytotoxicity, suggesting CYNK-101 may be a unique NK cell platform that preserves innate immune function in the presence of daratumumab.","CYNK-301 is a pre-clinical investigational next-generation chimeric antigen receptor-transduced natural killer (CAR-NK) cell therapy candidate that has the potential to overcome some of the challenges faced by NK therapies in treating R/R AML, including minimizing the burden of lymphodepletion while optimizing proliferation, persistence and efficacy. CYNK-301 incorporates membrane-bound IL-15 to enhance NK cell activation, proliferation and persistence, together with marrow homing and a targeted CAR to further enhance potential efficacy."]

Leadership

Robert J. Hariri, M.D., Ph.D. (Chairperson, Founder & CEO, Accomplished surgeon, biomedical scientist, and serial entrepreneur in biomedicine and aerospace. Founder of Anthrogenesis Corporation and co-founder of Human Longevity, Inc.), Andrew L. Pecora, M.D., F.A.C.P., C.P.E. (President, Renowned clinician and scientist with over 25 years of experience in biotechnology and healthcare. Previously served as President of the Physician Enterprise at Hackensack Meridian Health.), Anna Gosiewska, Ph.D. (R&D, Degenerative Diseases), Sharmila Koppisetti, M.D. (Clinical Development Immunology & Drug Safety), Tim Wilk (Technical Operations), Peter Diamandis, M.D. (Director), Geoffrey Shiu Fei Ling, M.D., Ph.D. (Director), Diane Parks (Director), Vincent LeVien (Director)

Verified data last updated: 2026-09-25